Nye hydroksimsyrederivater, farmasöytiske preparater inneholdende disse, og fremgangsmåter for fremstilling derav

• Main Authors: RADVANYI, ERZSEBET, JASZLITS, LASZLO, VERECZKEY, LASZLO, JEDNAKOVITS, ANDREA, MARVANYOS, EDE, UDVARDY-NAGY, ISTVANNE, UROGDI, LASZLO, BIRO, KATALIN, BARABAS, MIHALY
• Format: Patent
• Language: Norwegian
• Published: 05.11.1996
• Edition: 6
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; CHEMISTRY; HETEROCYCLIC COMPOUNDS; METALLURGY; ORGANIC CHEMISTRY

PCT No. PCT/HU95/00014 Sec. 371 Date Nov. 5, 1996 Sec. 102(e) Date Nov. 5, 1996 PCT Filed May 4, 1995 PCT Pub. No. WO95/30649 PCT Pub. Date Nov. 16, 1995Hydroximic acid derivatives possess anti-ischemic effects, and therefore, they are useful for treating ischemic states and diseases, such as myocardial ischemia (which may be induced by occlusion of coronary arteries). These derivatives include compounds of formula (I): wherein: X represents a halogen; Z represents an aromatic group, a pyridinyl group, a picolyl group, or a lutidyl group; and R represents an -A-N(R1)R2 group, wherein: R1 and R2 represent, independently from each other, hydrogen or an alkyl group; or R1 and R2, together with the adjacent nitrogen atom, form a 5- to 7-membered, saturated heterocyclic group optionally containing an additional nitrogen, oxygen, or sulfur atom, the heterocyclic group optionally being substituted by at least one alkyl group; and A represents a straight or branched chain alkylene group, as well as pharmaceutically acceptable acid addition salts thereof. The invention further relates to processes for preparing the above noted compounds, and pharmaceutical compositions containing these compounds or their pharmaceutically acceptable acid addition salts as an active ingredient. Additionally, the invention relates to intermediate compounds of formula II used in preparing the compounds of formula I. Formula II is as follows: In formula II, the variables Z and R have the same definitions provided above.